{
  "company_name": "Grifols, S.A.",
  "ticker": "GRF SM",
  "sector": "Consumers",
  "last_updated": "2025-01-20",
  "overview": {
    "business_description": "Spanish multinational pharmaceutical and chemical company. Global leader in plasma-derived medicines. Operations include Biopharma (plasma products), Diagnostic, Bio Supplies, and Hospital divisions.",
    "business_positives": [
      "Global leader in plasma derivatives",
      "Essential medicines with stable demand",
      "Positive rating outlooks from Moody's and Fitch",
      "Q1 2025: Revenue +7.4%, EBITDA +14.2%"
    ],
    "fatal_flaw": "Very high leverage (6.8x per credit facility); governance concerns from 2024; plasma collection costs",
    "ownership": "Grifols family (significant stake), Public",
    "public_private": "public",
    "recent_news": "S&P upgraded to BB- (Dec 2025). Completed €5.8bn refinancing. €1.3bn new Sr Sec Notes. Brookfield dropped takeover bid Nov 2024. SRAAS sale raised €1.6bn."
  },
  "ratings": {
    "moodys": {"rating": "B2", "outlook": "Positive", "date": "2025-05"},
    "sp": {"rating": "BB-", "outlook": "Stable", "date": "2024-12"},
    "fitch": {"rating": "B+", "outlook": "Positive", "date": "2024-11"}
  },
  "quick_assessment": {
    "period_end": "Q3 2024",
    "cffo": null,
    "total_debt": 9200,
    "interest_expense": null,
    "capex": null,
    "debt_due_one_year": 343,
    "cash_on_hand": null,
    "revolver_available": null
  },
  "key_ratios": {
    "debt_to_ebitda": 6.8,
    "ebitda_minus_capex_to_interest": null,
    "fcf_to_debt": null,
    "net_debt_to_ebitda": null
  },
  "trend_analysis": {
    "years": ["2024E", "2029E"],
    "revenue": [7000, 10000],
    "ebitda": [1800, 2900],
    "ebitda_margin": [],
    "total_debt": []
  },
  "debt_capitalization": [
    {"instrument": "7.125% Sr Sec Notes", "amount": 1300, "maturity": "May 2030", "coupon": "7.125%", "price": null, "ytw": null, "stw": null, "rating": "B1/BB-/BB"},
    {"instrument": "Sr Sec Notes (Apr 2024)", "amount": 1000, "maturity": "2029", "coupon": "", "price": null, "ytw": null, "stw": null, "rating": "B1/BB-/BB"},
    {"instrument": "Revolving Credit Facility", "amount": null, "maturity": "May 2027", "coupon": "", "price": null, "ytw": null, "stw": null, "rating": ""},
    {"instrument": "Sr Unsecured Notes", "amount": null, "maturity": "Various", "coupon": "", "price": null, "ytw": null, "stw": null, "rating": "Caa1/B/B-"}
  ],
  "maturity_schedule": {
    "year_1": null,
    "year_2": null,
    "year_3": null,
    "year_4": null,
    "year_5": null,
    "thereafter": null
  },
  "equity_market_value": {},
  "credit_opinion": {
    "summary": "Grifols is a highly leveraged but improving credit. The company addressed 2025 maturities through private placement and SRAAS stake sale. Positive outlooks from Moody's and Fitch suggest upgrade potential if deleveraging continues.",
    "key_risks": [
      "Very high leverage (6.8x) limits flexibility",
      "Governance concerns after 2024 short-seller report",
      "Plasma collection cost inflation",
      "Deleveraging path execution risk"
    ],
    "key_catalysts": [
      "Continued revenue and EBITDA growth",
      "Leverage reduction toward 4x target",
      "Further asset monetization options",
      "Rating upgrades with positive outlooks"
    ],
    "recommendation": "NEUTRAL - Improving but still highly leveraged"
  }
}
